title: The association of epsilon-aminocaproic acid with postoperative decrease in creatinine clearance in 1502 coronary bypass patients.
abstract: Renal dysfunction is a common serious complication after cardiac surgery. Reports of proteinuria and hyperkalemia after cardiac surgery with epsilon-aminocaproic acid (EACA) have therefore raised concerns for renal safety. Since EACA renders these markers unreliable, we used perioperative change in creatinine clearance (DCrCl) to test the hypothesis that EACA is associated with greater reductions in creatinine clearance after heart surgery, particularly for patients with renal disease. We evaluated data from all elective primary coronary bypass patients during EACA introduction at our institution (July 1, 1991-December 31, 1992; 10 g iv bolus pre-cardiopulmonary bypass, then 1 g/h for 5 h). DCrCl was calculated using preoperative (CrPre) and postoperative peak serum creatinine values, using the Cockroft-Gault equation. Patients with CrPre > or = 133 micromol/L were also separately analyzed. Evaluated patients (n = 1502, +/-EACA; 581/905, 16 exclusions) included 233 with CrPre > or = 133 micromol/L (+/-EACA; 98/135). Multivariate analyses confirmed several known risk factors, but no association between DCrCl and EACA in all patients (P: = 0.66), and the subgroup with CrPre > or = 133 micromol/L (P: = 0.42).
  
  
  CONCLUSIONS
  In a large population of primary Coronary Artery Bypass Graft including a subset with preoperative renal dysfunction, there were no postoperative reductions in creatinine clearance attributable to epsilon-aminocaproic (EACA) administration. This retrospective study suggests that moderate epsilon-aminocaproic acid dosing during cardiac surgery is safe for the kidney; however, this inference is based on a single marker of renal dysfunction and requires prospective confirmation using a variety of tests of renal function.
authors.affiliation: Departments of Anesthesiology and Medicine (Division of Nephrology), Duke University Medical Center, Durham, North Carolina 27710, USA. staff002@mc.duke.edu
authors.forename: M
authors.initials: M
authors.lastname: Stafford-Smith
authors.forename: B
authors.initials: B
authors.lastname: Phillips-Bute
authors.forename: D N
authors.initials: DN
authors.lastname: Reddan
authors.forename: J
authors.initials: J
authors.lastname: Black
authors.forename: M F
authors.initials: MF
authors.lastname: Newman
mesh_terms: D000368:Aged; D015119:Aminocaproic Acid / Q000009:adverse effects*; D000933:Antifibrinolytic Agents / Q000009:adverse effects*; D002315:Cardiopulmonary Bypass; D001026:Coronary Artery Bypass; D003404:Creatinine / Q000097:blood*; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies
chemical_list: D000933:Antifibrinolytic Agents; D003404:Creatinine; D015119:Aminocaproic Acid